Zogenix to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Zogenix (NASDAQ: ZGNX), a biopharmaceutical company, announced its participation in two investor conferences. Management will host fireside chats at the Guggenheim Virtual 3rd Annual Neuro/Immunology Conference on November 15, 2021, at 2:20 PM ET, and the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:20 PM ET. The chats will be webcast live and archived on Zogenix's Investor Relations website for 90 days. Zogenix develops therapies for rare diseases, including FINTEPLA® for Dravet syndrome and additional programs targeting various rare epilepsies.

EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3^rd Annual Neuro/Immunology Conference.

Guggenheim Virtual 3rd Annual Neuro/Immunology Conference Fireside Chat Details
Date:	Monday, November 15, 2021
Time:	2:20 PM Eastern Time

Stifel 2021 Virtual Healthcare Conference Fireside Chat Details
Date:	Tuesday, November 16, 2021
Time:	1:20 PM Eastern Time

The fireside chats will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

Zogenix
corpcomms@zogenix.com

Investors
Brian Ritchie 
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com

Media
Trish McCall, Porter Novelli
+1 (805) 390-3279 | trish.mccall@porternovelli.com

 

FAQ

What are the dates for Zogenix's investor conference fireside chats?

Zogenix's fireside chats are scheduled for November 15, 2021, at 2:20 PM ET for the Guggenheim Virtual 3rd Annual Neuro/Immunology Conference, and November 16, 2021, at 1:20 PM ET for the Stifel 2021 Virtual Healthcare Conference.

Where can I watch Zogenix's fireside chat webcasts?

The fireside chats can be watched live and archived for 90 days on Zogenix's Investor Relations website.

What is the focus of Zogenix's therapies?

Zogenix focuses on developing therapies for rare diseases, particularly for conditions like Dravet syndrome, Lennox-Gastaut syndrome, and TK2 deficiency.

What therapy has Zogenix developed for Dravet syndrome?

Zogenix has developed FINTEPLA® (fenfluramine) oral solution, which is approved for the treatment of seizures associated with Dravet syndrome.

What other development programs is Zogenix working on?

In addition to FINTEPLA, Zogenix has late-stage programs for Lennox-Gastaut syndrome and TK2 deficiency, and plans to study FINTEPLA in CDKL5 Deficiency Disorder (CDD).